Abstract
The seven-spanning transmembrane G-protein coupled receptor CXCR4, which specifically binds to the chemokine CXCL12, is expressed on many cell types, including various types of tumour cells. CXCR4 plays a crucial role in organ-specific metastasis, directing migration of malignant cells expressing this receptor toward microenvironments where the cognate ligand is secreted. CXCL12 has a direct growth and survival-promoting effect for various cancer cells and enhances moreover tumour angiogenesis by recruiting endothelial progenitor cells to tumours. Drugs which modulate the CXCL12/CXCR4 axis are therefore promising candidates in anti-cancer therapies. CXCR4 is also a coreceptor for human immunodeficiency virus type 1 (HIV-1) X4 virus and, as such, plays an important role in virus entry into target cells. Hence, antiviral agents that bind to CXCR4 are expected to inhibit HIV-1 entry. Here we review the structure, mechanism of action and biological activity of the main CXCR4 antagonists (peptide inhibitors, non-peptide antagonists, neutralizing antibodies, modified analogues of CXCL12) and agonists (CXCL12 peptide analogues) and discuss the CXCL12/CXCR4 axis as an important target in development of anti-tumoral and anti-HIV-1 therapies.
Keywords: CXCR4, CXCL12, antagonist, agonist, analogue, cancer, HIV-1, hematopoietic progenitor mobilization, cognate ligand, angiogenesis, human immunodeficiency virus type 1, peptide inhibitors,, chemokine receptors, G-protein coupled receptor (GPCR), bone marrow, lymph nodes, lung, brain, liver, peptide, Tachypleus tridentatus, Limulus polyphemus, TZ14004, TN14003, TC14012, 4F-benzoyl-TN14003, T-140-Based Cyclic Pentapeptides, Linear T140-Based Oligopeptides, tripeptide mimetics, p-fluorobenzoylated tripeptide mimetics, AMD3100, AMD3100-Based Non-Cyclam Compounds, Dipicolylamine zinc(II)-Based Compounds, HSEFFR-CPC-RFFESH, aberrant hematopoiesi, homodimerization, Epstein-Barr virus-encoded
Current Medicinal Chemistry
Title: The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Volume: 18 Issue: 4
Author(s): L. Patrussi and C. T. Baldari
Affiliation:
Keywords: CXCR4, CXCL12, antagonist, agonist, analogue, cancer, HIV-1, hematopoietic progenitor mobilization, cognate ligand, angiogenesis, human immunodeficiency virus type 1, peptide inhibitors,, chemokine receptors, G-protein coupled receptor (GPCR), bone marrow, lymph nodes, lung, brain, liver, peptide, Tachypleus tridentatus, Limulus polyphemus, TZ14004, TN14003, TC14012, 4F-benzoyl-TN14003, T-140-Based Cyclic Pentapeptides, Linear T140-Based Oligopeptides, tripeptide mimetics, p-fluorobenzoylated tripeptide mimetics, AMD3100, AMD3100-Based Non-Cyclam Compounds, Dipicolylamine zinc(II)-Based Compounds, HSEFFR-CPC-RFFESH, aberrant hematopoiesi, homodimerization, Epstein-Barr virus-encoded
Abstract: The seven-spanning transmembrane G-protein coupled receptor CXCR4, which specifically binds to the chemokine CXCL12, is expressed on many cell types, including various types of tumour cells. CXCR4 plays a crucial role in organ-specific metastasis, directing migration of malignant cells expressing this receptor toward microenvironments where the cognate ligand is secreted. CXCL12 has a direct growth and survival-promoting effect for various cancer cells and enhances moreover tumour angiogenesis by recruiting endothelial progenitor cells to tumours. Drugs which modulate the CXCL12/CXCR4 axis are therefore promising candidates in anti-cancer therapies. CXCR4 is also a coreceptor for human immunodeficiency virus type 1 (HIV-1) X4 virus and, as such, plays an important role in virus entry into target cells. Hence, antiviral agents that bind to CXCR4 are expected to inhibit HIV-1 entry. Here we review the structure, mechanism of action and biological activity of the main CXCR4 antagonists (peptide inhibitors, non-peptide antagonists, neutralizing antibodies, modified analogues of CXCL12) and agonists (CXCL12 peptide analogues) and discuss the CXCL12/CXCR4 axis as an important target in development of anti-tumoral and anti-HIV-1 therapies.
Export Options
About this article
Cite this article as:
Patrussi L. and T. Baldari C., The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480159
DOI https://dx.doi.org/10.2174/092986711794480159 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Daidzein and its Effects on Brain
Current Medicinal Chemistry The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry An Overview of Pathogenesis and Pathophysiology in Endometriosis
Current Women`s Health Reviews Patent Selections
Recent Patents on Biomarkers Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Role of Non-Coding RNA of Human Platelet in Cardiovascular Disease
Current Medicinal Chemistry Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Metabolomic Profiling for Selection of the Most Viable Embryos in Clinical IVF
Current Women`s Health Reviews The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Progress: Gynecologic Oncology Group Trials in Uterine Corpus Tumors
Reviews on Recent Clinical Trials Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV
Current Topics in Medicinal Chemistry